miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.

miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis that leads to peripheral cytopenias. We observed that SMAD7, a negative regulator of transforming growth factor-beta (TGF-β) receptor-I kinase, is markedly reduced in MDS and leads to ineffective hematopoiesis by overacti...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Bhagat, T, Zhou, L, Sokol, L, Kessel, R, Caceres, G, Gundabolu, K, Tamari, R, Gordon, S, Mantzaris, I, Jodlowski, T, Yu, Y, Jing, X, Polineni, R, Bhatia, K, Pellagatti, A, Boultwood, J, Kambhampati, S, Steidl, U, Stein, C, Ju, W, Liu, G, Kenny, P, List, A, Bitzer, M, Verma, A
Формат:	Conference item
Хэвлэсэн:	American Society of Hematology 2013

Ижил төстэй зүйлс

miR-21 mediates hematopoietic suppression in MDS by activating TGF-beta signaling
-н: Bhagat, T, зэрэг
Хэвлэсэн: (2013)

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.
-н: Zhou, L, зэрэг
Хэвлэсэн: (2008)

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.
-н: Zhou, L, зэрэг
Хэвлэсэн: (2011)

The impact of spliceosome mutations in MDS
-н: Jacqueline Boultwood, зэрэг
Хэвлэсэн: (2019-06-01)

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
-н: Caceres, G, зэрэг
Хэвлэсэн: (2013)

Recent advances in MDS mutation landscape: splicing and signalling
-н: Follo, MY, зэрэг
Хэвлэсэн: (2019)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
-н: Barreyro, L, зэрэг
Хэвлэсэн: (2012)

Aberrant Expression of DOCK4 Leads to Disruption of the F-Actin Skeleton and Altered Membrane Stability in MDS Erythroblasts and Mature Erythrocytes
-н: Sundaravel, S, зэрэг
Хэвлэсэн: (2012)

Aberrant Expression of DOCK4 Leads to Disruption of the F-Actin Skeleton and Altered Membrane Stability in MDS Erythroblasts and Mature Erythrocytes
-н: Sundaravel, S, зэрэг
Хэвлэсэн: (2012)

The role of innate immunity in MDS pathogenesis
-н: David A. Sallman, зэрэг
Хэвлэсэн: (2019-06-01)

High-resolution genomic profiling of myelodysplasia (MDS) by microarray comparative genomic hybridisation (CGH)
-н: Esoof, N, зэрэг
Хэвлэсэн: (2005)

High-resolution genomic profiling of myelodysplasia (MDS) by microarray comparative genomic hybridization (CGH).
-н: Esoof, N, зэрэг
Хэвлэсэн: (2006)

Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.
-н: Keerthivasan, G, зэрэг
Хэвлэсэн: (2014)

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
-н: Jadersten, M, зэрэг
Хэвлэсэн: (2005)

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
-н: Stahl, M, зэрэг
Хэвлэсэн: (2023)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
-н: Efficace, F, зэрэг
Хэвлэсэн: (2024)

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
-н: Malcovati, L, зэрэг
Хэвлэсэн: (2020)

MDS plus data acquisition system
-н: Stillerman, J.A., зэрэг
Хэвлэсэн: (2015)

Gene expression profiling in MDS and AML: potential and future avenues.
-н: Theilgaard-Mönch, K, зэрэг
Хэвлэсэн: (2011)

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.
-н: Will, B, зэрэг
Хэвлэсэн: (2012)

PP2A: The Achilles Heal in MDS with 5q Deletion
-н: David eSallman, зэрэг
Хэвлэсэн: (2014-09-01)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
-н: Fabio Efficace, зэрэг
Хэвлэсэн: (2024-05-01)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
-н: Follo, M, зэрэг
Хэвлэсэн: (2019)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
-н: Botezatu, L, зэрэг
Хэвлэсэн: (2016)

Downregulation of Ribosomal Proteins Is Seen in Non 5q-MDS
-н: Sohal, P, зэрэг
Хэвлэсэн: (2008)

MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results
-н: Sallman, D, зэрэг
Хэвлэсэн: (2022)

Generalized GM-MDS: Polynomial Codes Are Higher Order MDS
-н: Brakensiek, Joshua, зэрэг
Хэвлэсэн: (2024)

MDS Constacyclic Codes and MDS Symbol-Pair Constacyclic Codes
-н: Hai Q. Dinh, зэрэг
Хэвлэсэн: (2021-01-01)

Spliceosome mutations: 1 plus 1 does not always equal 2
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2020)

Reduced translation of GATA1 in Diamond-Blackfan anemia.
-н: Boultwood, J, зэрэг
Хэвлэсэн: (2014)

SF3B1 mutant myelodysplastic syndrome: Recent advances
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2020)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2016)

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
-н: Chen, J, зэрэг
Хэвлэсэн: (2022)

SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications
-н: Singh, S, зэрэг
Хэвлэсэн: (2020)

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
-н: Santini, V, зэрэг
Хэвлэсэн: (2014)

Energetic particle cross-field diffusion: Interaction with Magnetic Decreases (MDs)
-н: B. T. Tsurutani, зэрэг
Хэвлэсэн: (1999-01-01)

The weights in MDS codes
-н: Ezerman, Martianus Frederic, зэрэг
Хэвлэсэн: (2019)

Construction of MDS matrices
-н: Peng-fei LI, зэрэг
Хэвлэсэн: (2016-06-01)

Construction of MDS matrices
-н: Peng-fei LI, зэрэг
Хэвлэсэн: (2016-06-01)

What after MDS?
-н: Vijay Deshmukh
Хэвлэсэн: (2014-01-01)